CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kalaris Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kalaris Therapeutics Inc
628 Middlefield Road
Phone: (650) 249-2727p:650 249-2727 PALO ALTO, CA  94301  United States Ticker: KLRSKLRS
This company was Merged or Acquired on 3/18/2025.
This is a Subsidiary, click here for the Parent Company
Business Summary
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board David L.Hallal 57 5/17/2021 9/1/2018
Chief Executive Officer, Principal Executive Officer, Director AndrewOxtoby 51 3/18/2025 3/18/2025
Co-Founder, Chief Scientific Officer AnnLeen 47 1/1/2013 1/1/2013
7 additional Officers and Directors records available in full report.

Business Names
Business Name
AlloVir International Designated Activity Company
AlloVir Italia S.R.L.
AlloVir Securities Corporation
AlloVir U.S., Inc.
ALVR
KLRS

General Information
Number of Employees: 6 (As of 12/31/2024)
Outstanding Shares: 18,702,413 (As of 3/18/2025)
Shareholders: 52
Stock Exchange: NASD
Federal Tax Id: 831971007
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 8, 2025